| 09.30 | Coffee and registration |
| | |
| 10.00 | Session 1 Chair: Dr Irene François |
| | |
| 10.05 | Professor John Hardy, Institute of Neurology, University College London, UK |
| | Genetic analysis of neurodegenerative diseases |
| | |
| 10.40 | Professor Jean-Pierre Changeux, Institut Pasteur, France |
| | Allosteric receptors from electic organ to cognition: challenges for the discovery of new medicines for neurological disorders |
| | |
| 11.15 | Dr Andrew Thomas, F Hoffman-La Roche AG, Switzerland |
| | Treatment of cognitive dysfunction by selectively modulating the GABAA a5 receptor subtype |
| | |
| 11.50 | Lunch and Poster Session |
| | |
| 13.30 | Session 2 Chair: Dr Colin Bedford |
| | |
| 13.35 | Professor Kristian Strømgaard, University of Copenhagen, Denmark |
| | Targeting protein-protein interactions in the brain |
| | |
| 14.10 | Professor Simon Heales, UCL Institute of Child Health & Great Ormond Street Hospital, London, UK |
| | Potential Metabolic Causes of Parkinson’s Disease |
| | |
| 14.45 | Professor David Collier, Institute of Psychiatry, King’s College, London, UK |
| | Genetic susceptibility to schizophrenia, autism, intellectual disability and epilepsy |
| | |
| 15.20 | Tea |
| | |
| 16.05 | Session 3 Chair: Dr Klaus Rumpel |
| | |
| 16.10 | Professor Dominic Walsh, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Ireland |
| | Targeting synaptotoxic Abeta |
| | |
| 16.45 | Dr Dic Williams, Pfizer Pharma Therapeutics, Sandwich, UK |
| | The future of pain therapeutics; emerging mechanisms and molecules |
| | |
| 17.20 | Closing remarks |
